Fulgent Genetics Inc (NAS:FLGT)
$ 21.74 -0.37 (-1.67%) Market Cap: 650.55 Mil Enterprise Value: 368.33 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 74/100

Fulgent Genetics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2021 / 09:20PM GMT
Release Date Price: $79.47 (+1.08%)
Paul Kim
Fulgent Genetics, Inc. - CFO

Hello, this is Paul Kim. I'm the Chief Financial Officer of Fulgent Genetics. With me is Brandon Perthuis, our Chief Commercial Officer, who would like to give you an overview and our strategy going forward for Fulgent Genetics.

Fulgent was founded in 2011. We went public in 2016, primarily as a rare disease company. And in the several years following that, we've expanded our capabilities into areas such as germline cancer, women's reproductive health and sequencing as a service. We brought Brandon on with a number of senior sales and commercial individuals. We revamped our sales and commercial organization from 2017 into 2018. And then we also brought in Dr. Larry Weiss in 2021 to continue to strengthen our management team. And we've entered into the COVID business at the beginning part of 2020.

Brandon, then if you go to the next slide. In the most recent quarter, we've posted very, very strong results as a result of the continued progress in the company, both in terms of growth and the COVID as well as the non-COVID business . We have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot